Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

About Agios Pharmaceuticals

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AGIO
  • CUSIP:
Key Metrics:
  • Previous Close: $38.08
  • 50 Day Moving Average: $41.88
  • 200 Day Moving Average: $44.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.26
  • P/E Growth: 0.00
  • Market Cap: $1.45B
  • Outstanding Shares: 38,046,000
  • Beta: 1.98
Additional Links:
Companies Related to Agios Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (?)
Ratings Breakdown: 6 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $63.88 (67.96% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateFirmActionRatingPrice TargetDetails
8/19/2016BTIG ResearchInitiated CoverageNeutralView Rating Details
8/10/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$46.00View Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
6/13/2016Janney Montgomery ScottReiterated RatingNeutral$52.00 -> $47.00View Rating Details
6/13/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$50.00 -> $62.00View Rating Details
6/13/2016Canaccord GenuityUpgradeHold -> Buy$50.00 -> $90.00View Rating Details
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details
5/19/2016Leerink SwannReiterated RatingMarket Perform$56.00View Rating Details
5/18/2016SunTrust Banks Inc.Boost Price TargetBuy$57.00 -> $65.00View Rating Details
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00View Rating Details
11/9/2015Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
7/22/2015Northland SecuritiesInitiated CoverageOutperform$132.00View Rating Details
7/2/2015DesjardinsUpgradeHold -> BuyView Rating Details
6/2/2015Citigroup Inc.Initiated CoverageNeutral$132.00View Rating Details
5/8/2015MLV & Co.Initiated CoverageBuy$130.00View Rating Details
(Data available from 8/28/2014 forward)


Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.50)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.92)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.58)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 millionViewListenView Earnings Details
8/7/2014Q2($0.41)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.38)($0.39)ViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
Current Year EPS Consensus Estimate: $-4.8 EPS
Next Year EPS Consensus Estimate: $-5.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.48)($0.52)
Q2 20163($1.33)($1.15)($1.23)
Q3 20163($1.42)($1.26)($1.32)
Q4 20163($1.49)($0.91)($1.25)
(Data provided by Zacks Investment Research)


Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Agios Pharmaceuticals (NASDAQ:AGIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
DateHeadline logoAgios Pharmaceuticals : University Of Texas Investment Managment Co adds Agios Pharmaceuticals Inc (AGIO) to its portfolio (NASDAQ:AGIO) - August 27 at 8:08 AM logoAGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:AGIO) - August 27 at 8:08 AM logoHow These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics - PR Newswire (press release) (NASDAQ:AGIO) - August 26 at 11:30 AM logoETF’s with exposure to Agios Pharmaceuticals, Inc. : August 26, 2016 (NASDAQ:AGIO) - August 26 at 11:30 AM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:AGIO) - August 23 at 9:15 AM
News IconRatings & Crowd Appeal on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Post News (NASDAQ:AGIO) - August 21 at 8:08 AM logoAnalysts See Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Reporting EPS Of $-1.38 - (NASDAQ:AGIO) - August 21 at 8:08 AM
News IconStreet Consensus on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Post News (NASDAQ:AGIO) - August 19 at 3:53 PM logoWhy This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates (NASDAQ:AGIO) - August 19 at 3:53 PM logoCan Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Keep Up With Analyst Expectations? - Investor Newswire (NASDAQ:AGIO) - August 18 at 3:28 PM logoAGIOS PHARMACEUTICALS INC Financials (NASDAQ:AGIO) - August 17 at 3:24 PM logoAGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh (NASDAQ:AGIO) - August 16 at 8:41 PM logoCompany Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Appoints Andrew Hirsch as Chief Financial Officer - Smarter Analyst (NASDAQ:AGIO) - August 16 at 3:23 PM logoBRIEF-Agios Pharmaceuticals appoints Andrew Hirsch as chief financial officer (NASDAQ:AGIO) - August 16 at 11:58 AM logoCompany Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Appoints Andrew Hirsch as Chief Financial Officer (NASDAQ:AGIO) - August 16 at 11:58 AM logo7:31 am Agios Pharma names Andrew Hirsch as CFO, effective September 19 (NASDAQ:AGIO) - August 16 at 11:58 AM logoAgios Appoints Andrew Hirsch as Chief Financial Officer (NASDAQ:AGIO) - August 16 at 11:58 AM logoWill Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Hit $90 Price Target? - Investor Newswire (NASDAQ:AGIO) - August 15 at 3:24 PM logoMorning Alert: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Williams Companies, Inc. (NYSE:WMB), Summit State ... - KC Register (NASDAQ:AGIO) - August 15 at 10:37 AM logoVanguard Group Inc Significantly Lowers Its Holdings in Agios Pharmaceuticals, Inc. (AGIO) Stock Last Quarter - Finance Daily (NASDAQ:AGIO) - August 10 at 12:39 PM logoAgios Pharmaceuticals Inc. (AGIO) Drops 5.77% on August 08 (NASDAQ:AGIO) - August 9 at 9:34 PM logoAGIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:AGIO) - August 8 at 8:49 PM logoQ2 Earnings Report Card: Biotech - Benzinga (NASDAQ:AGIO) - August 8 at 3:23 PM logoETF’s with exposure to Agios Pharmaceuticals, Inc. : August 8, 2016 (NASDAQ:AGIO) - August 8 at 3:23 PM
News IconGood News at Fred Hutch (NASDAQ:AGIO) - August 6 at 11:07 AM logoAgios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus (NASDAQ:AGIO) - August 5 at 11:46 AM logoAgios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016 (NASDAQ:AGIO) - August 5 at 11:46 AM logoAgios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:AGIO) - August 5 at 11:46 AM logoAgios Reports Second Quarter 2016 Financial Results (NASDAQ:AGIO) - August 4 at 9:05 PM logoAgios (AGIO) Reports Wider-than-Expected Loss in Q2 (NASDAQ:AGIO) - August 4 at 9:05 PM logoBRIEF-Agios Pharmaceuticals reports qtrly loss per share $1.47 (NASDAQ:AGIO) - August 4 at 9:05 PM logoAgios Pharmaceuticals Inc Earnings Call (Q2 2016) (NASDAQ:AGIO) - August 4 at 9:05 PM logoEdited Transcript of AGIO earnings conference call or presentation 4-Aug-16 12:30pm GMT (NASDAQ:AGIO) - August 4 at 9:05 PM logoAgios Pharmaceuticals reports 2Q loss - Yahoo Finance (NASDAQ:AGIO) - August 4 at 11:53 AM logoAgios Pharmaceuticals reports 2Q loss (NASDAQ:AGIO) - August 4 at 11:53 AM logoMedical Product Stock Earnings on Aug 4: NXTM, AGIO & More (NASDAQ:AGIO) - August 3 at 11:55 AM logoWill Agios (AGIO) Disappoint Estimates in Q2 Earnings? (NASDAQ:AGIO) - August 2 at 3:21 PM logoAgios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016 (NASDAQ:AGIO) - July 28 at 4:01 PM logoCan Shares Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Hit $90? - Investor Newswire (NASDAQ:AGIO) - July 26 at 12:31 PM logoNew Broker Ratings For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - FTSE News (NASDAQ:AGIO) - July 25 at 3:33 PM
News IconStock Up Nicely This Week: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - TGP (NASDAQ:AGIO) - July 23 at 3:21 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - TGP (NASDAQ:AGIO) - July 22 at 3:21 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Rose 1.03%: Verizon Communications Inc. (NYSE:VZ), Canadian Solar ... - KC Register (NASDAQ:AGIO) - July 22 at 3:21 PM logoBroker Outlook For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Fiscal Standard (NASDAQ:AGIO) - July 21 at 3:21 PM
News IconBig Pharma’s cash flows in a flurry of partnerships (NASDAQ:AGIO) - July 20 at 10:35 PM
News IconStock Moving Lower for the Month; Investor Update on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily (NASDAQ:AGIO) - July 20 at 4:10 PM
News IconHow Many Agios Pharmaceuticals Inc (NASDAQ:AGIO)'s Analysts Are Bullish? - Press Telegraph (NASDAQ:AGIO) - July 20 at 4:10 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Updated Price Targets - FTSE News (NASDAQ:AGIO) - July 19 at 3:22 PM
News IconEquity Roundup: Stock Performance Focus on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Press Telegraph (NASDAQ:AGIO) - July 19 at 3:22 PM logoAgios Pharmaceuticals draws bullish bet (NASDAQ:AGIO) - July 19 at 1:11 PM


Agios Pharmaceuticals (NASDAQ:AGIO) Chart for Sunday, August, 28, 2016

Last Updated on 8/28/2016 by Staff